Ben Jacobs, the reporter who was assaulted by Montana congressional candidate Greg Gianforte, says Gianforte has reneged on what Jacobs believed was a commitment to grant him an interview.
Gianforte, a Republican businessman, was elected to the House on May 25, one day after he body-slammed Jacobs.
Jacobs is now going public about the dispute. He says Gianforte is continuing a “pattern of avoiding responsibility for his actions.”
Gianforte’s team, for its part, says the congressman was never offering an on-the-record interview — but that he will be happy to sit down with Jacobs for an off-the-record meeting. “Congressman Gianforte’s offer to Mr. Jacobs remains on the table,” a spokesman said Tuesday night.
Gianforte has spoken with some members of the media in Montana, but has kept a relatively low profile in his first two months on the job.
On June 12 Gianforte pleaded guilty to a misdemeanor assault charge. A Montana judge ordered him to complete 40 hours of community service and attend anger management classes.
Top 5 Stocks To Own For 2018: Smart(SFS)
- [By Shane Hupp]
Smart & Final (NYSE: SFS) and Kroger (NYSE:KR) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
- [By Lisa Levin]
Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
Arcadia Biosciences, Inc. (N
Top 5 Stocks To Own For 2018: SodaStream International Ltd.(SODA)
- [By Chris Lange]
SodaStream International Ltd. (NASDAQ: SODA) reported its fourth-quarter financial results before the markets opened on Wednesday. The company said that it had $1.13 in earnings per share (EPS) on $157.7 million in revenue, which compares with consensus estimates from Thomson Reuters of $0.80 in EPS on revenue of $151.57 million. In the same period of last year, it said it had EPS of $0.71 and $131.8 million in revenue.
- [By Demitrios Kalogeropoulos]
SodaStream(NASDAQ:SODA) recently announced surprisingly strong first-quarter earnings as sales growth sped up to a 25% pace and profitability improved. The seller of at-home carbonated beverage machines is benefiting from a long-term trend of rising global demand for sparkling water.
- [By Jeremy Bowman]
I’m talking aboutSodaStream International(NASDAQ:SODA), of course, the Israeli do-it-yourself sparkling water specialist. Shares of SodaStream sold off following the earnings report on Wednesday even though the company once again beat earnings and revenue estimates. Below were the key figures from the first-quarter report.
- [By Stephan Byrd]
SodaStream (NASDAQ:SODA)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Group in a research note issued to investors on Wednesday. They currently have a $82.00 price target on the stock. Jefferies Group’s target price suggests a potential downside of 5.87% from the stock’s current price. Jefferies Group also issued estimates for SodaStream’s Q2 2018 earnings at $0.74 EPS, FY2018 earnings at $3.55 EPS, Q1 2019 earnings at $0.88 EPS, Q2 2019 earnings at $0.79 EPS and Q1 2020 earnings at $0.89 EPS.
Top 5 Stocks To Own For 2018: Ryder System Inc.(R)
- [By Joseph Griffin]
Media stories about Ryder (NYSE:R) have trended somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ryder earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the transportation company an impact score of 44.4340282605262 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
- [By Logan Wallace]
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Ryder (R) Will Post Quarterly Sales of $1.87 Billion” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at www.tickerreport.com/banking-finance/3377804/zacks-brokerages-anticipate-ryder-r-will-post-quarterly-sales-of-1-87-billion.html.
- [By Shane Hupp]
Mackay Shields LLC bought a new stake in shares of Ryder (NYSE:R) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 97,749 shares of the transportation company’s stock, valued at approximately $7,115,000. Mackay Shields LLC owned about 0.18% of Ryder at the end of the most recent reporting period.
Top 5 Stocks To Own For 2018: Ultragenyx Pharmaceutical Inc.(RARE)
- [By Joseph Griffin]
BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.
A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.
- [By Todd Campbell]
A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that’s successfully developed drugs for rare diseases.
- [By Chris Lange]
Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.
- [By Shane Hupp]
These are some of the media headlines that may have effected Accern’s scoring:
Get Ultragenyx Pharmaceutical alerts:
Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)
A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.
Top 5 Stocks To Own For 2018: PennyMac Mortgage Investment Trust(PMT)
- [By Stephan Byrd]
Pennymac Mortgage Investment (NYSE:PMT) – Equities researchers at Wedbush lifted their Q1 2019 earnings per share estimates for shares of Pennymac Mortgage Investment in a research note issued to investors on Thursday, May 10th. Wedbush analyst J. Weaver now anticipates that the real estate investment trust will post earnings per share of $0.36 for the quarter, up from their previous estimate of $0.34. Wedbush also issued estimates for Pennymac Mortgage Investment’s Q2 2019 earnings at $0.43 EPS, Q3 2019 earnings at $0.43 EPS, Q4 2019 earnings at $0.52 EPS and FY2019 earnings at $1.74 EPS.
- [By Stephan Byrd]
Pennymac Mortgage Investment (NYSE:PMT) shares reached a new 52-week high and low on Monday . The company traded as low as $18.60 and last traded at $18.62, with a volume of 19306 shares changing hands. The stock had previously closed at $18.50.